Pemvidutide · PERFORMA
The sponsor started PERFORMA in August 2026 and anticipates 52-week data in 2029. Histology findings and the longer-term clinical-outcomes endpoint must not be conflated. pemvidutide — phase 3 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH). NCT07795164 lists Clinical Outcome Event as a primary outcome (Baseline through end of study (approximately Month 60)). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2028-12 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- The registry lists 3 primary outcome measures. A market must explicitly specify which endpoint or conjunction resolves YES; this card highlights one measure only.
Primary evidence
Sponsor outlook: 2029 data — no exact day
Potential outcome market
Will pemvidutide meet the prespecified primary endpoint in NCT07795164 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.